Navigation Links
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
Date:6/8/2009

ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $33.0 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria in the long-term treatment of type 2 diabetes mellitus. All inquiries regarding the Phase 2 data presented at ADA, or about the development of Syncria, should be directed to the contacts provided by GSK. To view the GSK press release, please click here.

For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company's web site at www.hgsi.com.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. (Nasdaq: HGSI)

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has completed shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to FDA's approval of the Company's Biologics License Application for ABthrax. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

    Media Contact:
    Jerry Parrott
    Vice President, Corporate Communications
    301-315-2777

    Investor Contact:
    Peter Vozzo
    Senior Director, Investor Relations
    301-251-6003


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
(Date:2/10/2016)... 10, 2016 --> ... & Gas), and Spectroscopy Market by Industry (Oil & Gas, ... & Paper, Metal & Mining, and Others), And Geography ... global market is expected to grow to USD 3.9 ... between 2015 and 2020. Browse 82 market ...
(Date:2/10/2016)... CSI Specialty Group (CSI) expanded its specialty ... Specialty Pharmacy Podcast. A free, weekly show, the Specialty ... education, discussion and context amongst specialty pharmacy peers and ... --> The Specialty Pharmacy Podcast, hosted by industry ... Suzette DiMascio, CHE, CMCE, CPC, is available for streaming ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... change in their patients. Research shows that the Goal Attainment Scale (GAS) captures ... overcome this challenge and learn more about the Goal Attainment Scale, Education Resources ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at Ibis ... prestigious Distinguished Emerald Club of the World award, as determined by the annual ... the most respected trade publications serving private clubs. , “We’d like to congratulate ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | Ticket ... Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation , ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of ... in the state still face a lot of restrictions as to where they can ... for private, personal use” and that cannabis “may not be consumed openly or publicly.” ...
Breaking Medicine News(10 mins):